Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey - Sorbonne Université Accéder directement au contenu
Article Dans Une Revue RMD Open Année : 2021

Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey

Sebastian Eduardo Sattui
Jean Liew
  • Fonction : Auteur
Kevin Kennedy
Emily Sirotich
Michael Putman
  • Fonction : Auteur
Tarin Moni
  • Fonction : Auteur
Akpabio Akpabio
Deshiré Alpízar-Rodríguez
Inita Bulina
  • Fonction : Auteur
Richard Conway
Aman Dev Singh
  • Fonction : Auteur
Eimear Duff
  • Fonction : Auteur
Karen Durrant
  • Fonction : Auteur
Tamer Gheita
  • Fonction : Auteur
Catherine Hill
  • Fonction : Auteur
Richard Howard
  • Fonction : Auteur
Bimba Hoyer
  • Fonction : Auteur
Evelyn Hsieh
  • Fonction : Auteur
Lina El Kibbi
  • Fonction : Auteur
Adam Kilian
  • Fonction : Auteur
Alfred Hyoungju Kim
David Liew
  • Fonction : Auteur
Chieh Lo
  • Fonction : Auteur
Bruce Miller
  • Fonction : Auteur
Serena Mingolla
  • Fonction : Auteur
Michal Nudel
  • Fonction : Auteur
Candace Palmerlee
  • Fonction : Auteur
Jasvinder Singh
Namrata Singh
  • Fonction : Auteur
Manuel Francisco Ugarte-Gil
John Wallace
  • Fonction : Auteur
Kristen Young
  • Fonction : Auteur
Suleman Bhana
  • Fonction : Auteur
Wendy Costello
  • Fonction : Auteur
Rebecca Grainger
  • Fonction : Auteur
Pedro Machado
Philip Robinson
Paul Sufka
  • Fonction : Auteur
Zachary Wallace
  • Fonction : Auteur
Jinoos Yazdany
  • Fonction : Auteur
Carly Harrison
  • Fonction : Auteur
Maggie Larché
  • Fonction : Auteur
Mitchell Levine
  • Fonction : Auteur
Gary Foster
  • Fonction : Auteur
Lehana Thabane
  • Fonction : Auteur
Lisa Rider
  • Fonction : Auteur
Jonathan Hausmann
Julia Simard
Jeffrey Sparks

Résumé

Background We describe the early experiences of adults with systemic rheumatic disease who received the COVID-19 vaccine. Methods From 2 April to 30 April 2021, we conducted an online, international survey of adults with systemic rheumatic disease who received COVID-19 vaccination. We collected patient-reported data on clinician communication, beliefs and intent about discontinuing disease-modifying antirheumatic drugs (DMARDs) around the time of vaccination, and patient-reported adverse events after vaccination. Results We analysed 2860 adults with systemic rheumatic diseases who received COVID-19 vaccination (mean age 55.3 years, 86.7% female, 86.3% white). Types of COVID-19 vaccines were Pfizer-BioNTech (53.2%), Oxford/AstraZeneca (22.6%), Moderna (21.3%), Janssen/Johnson & Johnson (1.7%) and others (1.2%). The most common rheumatic disease was rheumatoid arthritis (42.3%), and 81.2% of respondents were on a DMARD. The majority (81.9%) reported communicating with clinicians about vaccination. Most (66.9%) were willing to temporarily discontinue DMARDs to improve vaccine efficacy, although many (44.3%) were concerned about rheumatic disease flares. After vaccination, the most reported patient-reported adverse events were fatigue/somnolence (33.4%), headache (27.7%), muscle/joint pains (22.8%) and fever/chills (19.9%). Rheumatic disease flares that required medication changes occurred in 4.6%. Conclusion Among adults with systemic rheumatic disease who received COVID-19 vaccination, patient-reported adverse events were typical of those reported in the general population. Most patients were willing to temporarily discontinue DMARDs to improve vaccine efficacy. The relatively low frequency of rheumatic disease flare requiring medications was reassuring.

Dates et versions

hal-03994609 , version 1 (17-02-2023)

Identifiants

Citer

Sebastian Eduardo Sattui, Jean Liew, Kevin Kennedy, Emily Sirotich, Michael Putman, et al.. Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open, 2021, 7 (3), pp.e001814. ⟨10.1136/rmdopen-2021-001814⟩. ⟨hal-03994609⟩
29 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More